Today: 9 June 2026
PayPal stock price rebounds as Cantor slashes target and Wall Street looks to CEO handover
9 February 2026
2 mins read

PayPal stock price rebounds as Cantor slashes target and Wall Street looks to CEO handover

NEW YORK, Feb 9, 2026, 15:46 (EST) — Regular session

  • PayPal shares were up roughly 1.7% at $41.12 in afternoon trading.
  • Cantor Fitzgerald trimmed its 12-month price target down to $42, sticking with a neutral rating.
  • Investors are weighing if new leadership will be enough to jumpstart growth in PayPal’s core checkout business.

PayPal shares gained 1.7% to finish at $41.12 on Monday, defying choppy trading across the payments sector as investors digested another price target reduction from Wall Street.

PayPal’s latest move comes as the company tries to regain traction following a board-driven leadership shakeup and a gloomy profit forecast that rattled the stock just last week. As a key player in digital payments, PayPal’s fortunes often echo across the fintech space when signs of stability emerge.

Cantor Fitzgerald cut PayPal’s price target to $42 from $60 on Monday, while sticking with a neutral rating, data from Benzinga showed. The price target reflects where brokers think the stock might land within the next year.

PayPal announced Feb. 3 that Enrique Lores, a longtime HP executive, will step in as CEO starting March 1, while David W. Dorman takes over as independent chair of the board. “Enrique is widely recognized as a visionary leader,” Dorman said in the company’s statement. SEC

According to an SEC filing related to the leadership shift, PayPal disclosed that Lores’s base salary is set at $1.45 million and he’s getting a sign-on equity grant. Interim CEO Jamie Miller, on the other hand, picked up a $3 million cash retention award.

Last week, PayPal’s board criticized the “pace of change and execution” under former CEO Alex Chriss, saying it fell short as rivals ramped up the pressure in online checkout. “We will further strengthen the culture of innovation … executing with greater speed and precision,” Lores said. SEC

PayPal rolled out its leadership changes as it posted its holiday-quarter results, falling short on both earnings and its profit outlook for 2026, which trailed Wall Street forecasts. The company pointed to weakness among some retail merchants and a notable slowdown in “branded checkout”—that is, the familiar PayPal button shoppers click at online retailers. Competition from Apple and Google intensified, dragging on growth, according to a Reuters report. Reuters

U.S. stocks picked up steam Monday, with tech shares bouncing back after last week’s AI-fueled selloff. “You’ve a sharply oversold market where a little bit of good news can go a long way,” said Keith Lerner, chief investment officer at Truist Advisory Services. Reuters

The focus for PayPal isn’t just one quarter. The real question: Can it halt share losses at checkout and rekindle traction with major merchants—without bleeding margin? Investors keep hearing about “near-term” steps in progress, though specifics on timing are still vague.

There’s a risk lurking here. Should consumer spending remain patchy, and rivals keep squeezing PayPal on mobile wallets and buy-now-pay-later, the company could be looking at more estimate downgrades—maybe even a fresh expectations reset, new CEO or not.

Traders now turn to U.S. payrolls on Wednesday, then consumer inflation figures set for Friday. PayPal is also in focus, with markets eyeing any fresh signals on priorities ahead of Lores stepping in as CEO March 1.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Uber’s new ride-booking kiosks and Adyen expansion spotlight fintech’s 2026 embedded-finance push
Previous Story

Uber’s new ride-booking kiosks and Adyen expansion spotlight fintech’s 2026 embedded-finance push

Silver price jumps again as dollar slips — here’s what traders watch next
Next Story

Silver price jumps again as dollar slips — here’s what traders watch next

Go toTop